SGMT (STOCKS)
Sagimet Biosciences Inc. Series A Common Stock
$5.420000
+0.120000 (+2.26%)
Prev close: $5.300000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- David A. Happel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $176.61M
- Employees
- 14
- P/E (TTM)
- -3.43
- P/B (TTM)
- 1.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.29 | $-0.41 | +0.1249 | +30.10% |
|
Sep 2025 (Q3)
|
$-0.40 | $-0.39 | -0.0067 | -1.70% |
|
Jun 2025 (Q2)
|
$-0.32 | $-0.52 | +0.1976 | +38.18% |
|
Mar 2025 (Q1)
|
$-0.56 | $-0.68 | +0.1192 | +17.55% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $56.89M |
| Research and Development | $39.05M |
| Other Operating Expenses | $17.84M |
| Operating Income/Loss | -$56.89M |
| Income/Loss From Continuing Operations After Tax | -$51.04M |
| Income/Loss From Continuing Operations Before Tax | -$51.04M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$51.04M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$51.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$51.04M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.58 |
| Diluted Earnings Per Share | -$1.58 |
| Basic Average Shares | 32,345,525 |
| Diluted Average Shares | 32,345,525 |
| Assets | $116.48M |
| Current Assets | $116.40M |
| Cash | $113.10M |
| Other Current Assets | $3.30M |
| Noncurrent Assets | $78.00K |
| Liabilities | $5.10M |
| Current Liabilities | $5.10M |
| Accounts Payable | $1.31M |
| Wages | $1.62M |
| Other Current Liabilities | $2.18M |
| Noncurrent Liabilities | $0.00 |
| Equity | $111.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $111.38M |
| Liabilities And Equity | $116.48M |
| Net Cash Flow From Operating Activities | -$45.65M |
| Net Cash Flow From Operating Activities, Continuing | -$45.65M |
| Net Cash Flow From Investing Activities | $4.56M |
| Net Cash Flow From Investing Activities, Continuing | $4.56M |
| Net Cash Flow From Financing Activities | $275.00K |
| Net Cash Flow From Financing Activities, Continuing | $275.00K |
| Net Cash Flow | -$40.82M |
| Net Cash Flow, Continuing | -$40.82M |
| Comprehensive Income/Loss | -$51.15M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$51.15M |
| Other Comprehensive Income/Loss | -$51.15M |